Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers

被引：22
|
作者：
Arner, Emily N. [1 ,2 ]
Du, Wenting [1 ,2 ]
Brekken, Rolf A. [1 ,2 ,3 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Canc Biol Grad Program, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA
来源：
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词：
EMT; KRAS; metastasis; TBK1; AXL; drug resistance; TO-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASE; PANCREATIC DUCTAL ADENOCARCINOMA; SIGNATURE PREDICTS RESISTANCE; SMALL-MOLECULE INHIBITION; KAPPA-B ACTIVATION; CELL-GROWTH; K-RAS; CHROMOSOMAL INSTABILITY; SIGNALING PATHWAY;
D O I：
10.3389/fonc.2019.01049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cellular plasticity, a feature associated with epithelial-to-mesenchymal transition (EMT), contributes to tumor cell survival,migration, invasion, and therapy resistance. Phenotypic plasticity of the epithelium is a critical feature in multiple phases of human cancer in an oncogene- and tissue-specific context. Many factors can drive epithelial plasticity, including activating mutations in KRAS, which are found in an estimated 30% of all cancers. In this review, we will introduce cellular plasticity and its effect on cancer progression and therapy resistance and then summarize the drivers of EMT with an emphasis on KRAS effector signaling. Lastly, we will discuss the contribution of cellular plasticity to metastasis and its potential clinical implications. Understanding oncogenic KRAS cellular reprogramming has the potential to reveal novel strategies to control metastasis in KRAS-driven cancers.
引用
收藏
页数：15
相关论文
共 50 条
  • [21] Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
    Mandar Deepak Muzumdar
    Kimberly Judith Dorans
    Katherine Minjee Chung
    Rebecca Robbins
    Tuomas Tammela
    Vasilena Gocheva
    Carman Man-Chung Li
    Tyler Jacks
    Nature Communications, 7
  • [22] Treatment modalities in KRAS-driven cancer
    Tyson, Darren R.
    Singh, Neetu
    Bhavar, Prashant K.
    Sarma, Partha Pratim
    Surampudi, Uday Kumar
    Katike, Sathish
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [23] A treatment strategy for KRAS-driven tumors
    Mai, Trang T.
    Lito, Piro
    NATURE MEDICINE, 2018, 24 (07) : 902 - 904
  • [24] The Role of an Intermediate Conformation of SHP2 in the MEK Pathway of KRAS-Driven Cancers
    Shannon, Daniel
    Poetker, Gavin
    Kaplan, Donnie
    Gruber, Weston
    Pease, Emmet
    McCloud, Brandon
    Allen, Jake
    Connolly, Connor
    Diao, JiaJie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S791 - S791
  • [25] Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers
    Hai, Josephine
    Liu, Shengwu
    Bufe, Lauren
    Do, Khanh
    Chen, Ting
    Wang, Xiaoen
    Ng, Christine
    Li, Shuai
    Tsao, Ming-Sound
    Shapiro, Geoffrey I.
    Wong, Kwok-Kin
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6993 - 7005
  • [26] Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
    Muzumdar, Mandar Deepak
    Dorans, Kimberly Judith
    Chung, Katherine Minjee
    Robbins, Rebecca
    Tammela, Tuomas
    Gocheva, Vasilena
    Li, Carman Man-Chung
    Jacks, Tyler
    NATURE COMMUNICATIONS, 2016, 7
  • [27] KRAS-DRIVEN CANCERS ARE DEPENDENT ON METTL13-MEDIATED eEF1A METHYLATION
    不详
    CANCER DISCOVERY, 2019, 9 (02) : 163 - 163
  • [28] Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
    Dietrich A. Ruess
    Guus J. Heynen
    Katrin J. Ciecielski
    Jiaoyu Ai
    Alexandra Berninger
    Derya Kabacaoglu
    Kivanc Görgülü
    Zahra Dantes
    Sonja M. Wörmann
    Kalliope N. Diakopoulos
    Angeliki F. Karpathaki
    Marlena Kowalska
    Ezgi Kaya-Aksoy
    Liang Song
    Eveline A. Zeeuw van der Laan
    María P. López-Alberca
    Marc Nazaré
    Maximilian Reichert
    Dieter Saur
    Mert M. Erkan
    Ulrich T. Hopt
    Bruno Sainz
    Walter Birchmeier
    Roland M. Schmid
    Marina Lesina
    Hana Algül
    Nature Medicine, 2018, 24 : 954 - 960
  • [29] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    David A. Barbie
    Pablo Tamayo
    Jesse S. Boehm
    So Young Kim
    Susan E. Moody
    Ian F. Dunn
    Anna C. Schinzel
    Peter Sandy
    Etienne Meylan
    Claudia Scholl
    Stefan Fröhling
    Edmond M. Chan
    Martin L. Sos
    Kathrin Michel
    Craig Mermel
    Serena J. Silver
    Barbara A. Weir
    Jan H. Reiling
    Qing Sheng
    Piyush B. Gupta
    Raymond C. Wadlow
    Hanh Le
    Sebastian Hoersch
    Ben S. Wittner
    Sridhar Ramaswamy
    David M. Livingston
    David M. Sabatini
    Matthew Meyerson
    Roman K. Thomas
    Eric S. Lander
    Jill P. Mesirov
    David E. Root
    D. Gary Gilliland
    Tyler Jacks
    William C. Hahn
    Nature, 2009, 462 : 108 - 112
  • [30] Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers
    Koundinya, Malvika
    Sudhalter, Judith
    Courjaud, Albane
    Lionne, Bruno
    Touyer, Gaetan
    Bonnet, Luc
    Menguy, Isabelle
    Schreiber, Isabelle
    Perrault, Christelle
    Vougier, Stephanie
    Benhamou, Brigitte
    Zhang, Bailin
    He, Timothy
    Gao, Qiang
    Gee, Patricia
    Simard, Daniel
    Castaldi, M. Paola
    Tomlinson, Ronald
    Reiling, Stephan
    Barrague, Matthieu
    Newcombe, Richard
    Cao, Hui
    Wang, Yanjun
    Sun, Fangxian
    Murtie, Joshua
    Munson, Mark
    Yang, Eric
    Harper, David
    Bouaboula, Monsif
    Pollard, Jack
    Grepin, Claudine
    Garcia-Echeverria, Carlos
    Cheng, Hong
    Adrian, Francisco
    Winter, Christopher
    Licht, Stuart
    Cornella-Taracido, Ivan
    Arrebola, Rosalia
    Morris, Aaron
    CELL CHEMICAL BIOLOGY, 2018, 25 (06): : 705 - +
12345